Technical Analysis for RAPT - RAPT Therapeutics, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 4.01 | -0.99% | -0.04 |
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| NR7 | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Bullish Engulfing | Bullish | -0.99% | |
| Wide Bands | Range Expansion | -0.99% | |
| Oversold Stochastic | Weakness | -0.99% | |
| New 52 Week Closing Low | Bearish | 1.52% | |
| New 52 Week Low | Weakness | 1.52% | |
| Wide Bands | Range Expansion | 1.52% | |
| Down 3 Days in a Row | Weakness | 1.52% |
| Alert | Time |
|---|---|
| Possible NR7 | 2 days ago |
| 60 Minute Opening Range Breakdown | 2 days ago |
| 60 Minute Opening Range Breakout | 2 days ago |
| Up 5% | 2 days ago |
| 10 DMA Resistance | 2 days ago |
Get a Trading Assistant
- Earnings date: 05/09/2024
RAPT Therapeutics, Inc. Description
RAPT Therapeutics, Inc., a clinical stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. The company develops small molecules that are designed to modulate the critical immune responses underlying these diseases. Its lead oncology drug candidate is FLX475 for the treatment of a range of tumors; and RPT193, a CCR4 antagonist for allergic inflammatory disease. The company is also pursuing a range of targets, including general control nonderepressible and hematopoietic progenitor kinase for the treatment of cancer. RAPT Therapeutics, Inc. was founded in 2015 and is headquartered in South San Francisco, California. RAPT Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Company.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Cancer Life Sciences Disease Immunology Pharmacy Treatment Of Cancer Tumor Inflammatory Diseases Specialty Drugs Small Molecule Therapies Immune Response
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 27.35 |
| 52 Week Low | 3.88 |
| Average Volume | 872,577 |
| 200-Day Moving Average | 14.67 |
| 50-Day Moving Average | 6.99 |
| 20-Day Moving Average | 5.02 |
| 10-Day Moving Average | 4.20 |
| Average True Range | 0.46 |
| RSI (14) | 28.06 |
| ADX | 37.28 |
| +DI | 15.66 |
| -DI | 36.21 |
| Chandelier Exit (Long, 3 ATRs) | 7.19 |
| Chandelier Exit (Short, 3 ATRs) | 5.27 |
| Upper Bollinger Bands | 8.20 |
| Lower Bollinger Band | 1.85 |
| Percent B (%b) | 0.34 |
| BandWidth | 126.48 |
| MACD Line | -1.00 |
| MACD Signal Line | -1.06 |
| MACD Histogram | 0.0654 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 4.43 | ||||
| Resistance 3 (R3) | 4.47 | 4.38 | 4.36 | ||
| Resistance 2 (R2) | 4.38 | 4.27 | 4.36 | 4.34 | |
| Resistance 1 (R1) | 4.19 | 4.20 | 4.15 | 4.15 | 4.31 |
| Pivot Point | 4.10 | 4.10 | 4.07 | 4.08 | 4.10 |
| Support 1 (S1) | 3.91 | 3.99 | 3.87 | 3.87 | 3.71 |
| Support 2 (S2) | 3.82 | 3.92 | 3.80 | 3.68 | |
| Support 3 (S3) | 3.63 | 3.82 | 3.66 | ||
| Support 4 (S4) | 3.59 |
